REGENXBIO Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Rockville, USA
Total Funding:$247M
Industry:Biotech
Founded:2008
Lead Investor(s):Morgan Stanley, BofA Merrill Lynch
Press
Claim your profile

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • REGENXBIO's estimated annual revenue is currently $218.5M per year.
  • REGENXBIO received $201.8M in venture funding in August 2018.
  • REGENXBIO's estimated revenue per employee is $788,827
  • REGENXBIO's total funding is $247M.

Employee Data

  • REGENXBIO has 277 Employees.
  • REGENXBIO grew their employee count by 1% last year.
  • REGENXBIO currently has 23 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
DiaCarta
$7M4510%N/A
Mission Bio
$12.7M823%N/A
Intralytix
$4.7M30N/AN/A
Ohana Bioscienc...
$8.7M5660%N/A
Hydromer
$10.4M67N/AN/A
Tango Therapeut...
$12.9M8338%N/A
Geron Corporati...
N/A205N/AN/A
OriGene Technol...
$15.7M101-4%N/A
Databean...seed...
$1.4M9N/AN/A
Althea Technolo...
$22.3M144N/AN/A
Missing a competitor? Contribute!?
Submit

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adenoassociated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and thirdparty NAV Technology Platform licensees.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

277

Number of Employees

$218.5M

Revenue (est)

23

Current Jobs

1%

Employee Growth %

$247M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Ken MillsPresident & Chief Executive OfficerEmail Available
Kenneth MillsCEO/PresidentEmail Available
Vit VasistaCFOEmail Available
Sara Garon BerlVice President, Law And PolicyEmail Available
Ken TroutDirector Data ManagementEmail Available
Anahita NikzadDirector Clinical OperationsEmail Available
Amanda FlemingConference Project ManagerEmail Available
Matthew CarneyDirector of Data ManagementEmail Available
Paul BrobergFacilities ManagerEmail Available
Avanti GhanekarDirector Of Clinical DevelopmentEmail Available

REGENXBIO News

09/09/2019 - This Rockville biotech has added another deal to its growth plan

RegenxBio Inc. just locked in another deal — this one with a company working to treat eye diseases. The Rockville biotech has reached a ...

09/04/2019 - REGENXBIO Announces Exclusive Worldwide Option and ...

REGENXBIO expands RGX-314 gene therapy program to evaluate Clearside's proprietary, in-office SCS Microinjector™ platform targeting ...

08/28/2019 - REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to ...

REGENXBIO Funding

DateAmountRoundLead InvestorsReference
2013-11-11$7.9MUndisclosedArticle
2015-01-22$30.0MCVenrockArticle
2015-05-21$70.5MDVivo CapitalArticle
2018-08-09$175.0MUndisclosedMorgan StanleyArticle
2018-08-13$201.8MUndisclosedMorgan StanleyArticle

REGENXBIO Executive Hires

DateNameTitleReference
2014-10-29Stephen YooChief Medical OfficerArticle

REGENXBIO Acquisitions

DateCompany NameAmountNotesReference
2017-08-28Dimension TherapeuticsArticle